SecBot SecBot

PVLA

PALVELLA THERAPEUTICS, INC.
Nasdaq· Pharmaceutical Preparations· Inc. NV· CIK 0001583648 Biotech & Drug Discovery
$144.60 −7.88 (−5.17%)
Nov 16 4:00 PM ET · prev $152.48
Market cap
$2.2B
Mid cap
Consensus
Buy
96% Buy or better · 23 analysts
Median target
🔒 Subscribers only
1 year
+77.1%
from $81.64 · Nov 17
30 days
+17.6%
from $122.96
52-week range
$76.43–175.92
−18% from high · low Feb 5
Avg volume 20D
285.1K
shares / day
Short interest
2.60M
≈17.8% of shares · +8.1%
Days to cover
11.5
at average volume
Insider net
−$10.1M
0 buyers · 3 sellers · since Sep 11
New fund stakes
2
Q3 2026 13F · 0 exits
Filing reports
26
analyzed by SecBot
SecBot read BULLISH 13 reports · 90 days
Balance 1 bearish · 3 bullish · 9 neutral oldest → newest, height = score
Avg score ·High conf. 6/13 ·Next FDA decision date, Feb 28, 2027

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    3 insiders sold $10.1M.

  • InstitutionsBULLISH

    Q3 2026: 27 added (2 new), 14 trimmed or exited. Largest new: Westfield Capital Management $54.6M, William Blair Investment Management $26.9M.

  • AnalystsBULLISH

    22 of 23 rate it Buy or better.

  • Short sellersSTEADY

    Short interest +8.1% to 2.60M shares. 11.5 days to cover, ≈17.8% of shares.

  • TrendUPTREND

    1% above its 50-day average.

Who's buying

13F· Q3 2026
2
new positions
0
exits
$81.5M
in new stakes
FundMoveSharesValue
WESTFIELD CAPITAL MANAGEMENT CO LPNEW396,045$54.6M
MARSHALL WACE, LLPDOUBLED329,799$45.5M
Invesco Ltd.DOUBLED312,729$43.1M
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLCNEW195,070$26.9M
FMR LLCTRIM126,767$17.5M
UBS Group AGADD118,459$16.3M
Aberdeen Group plcTRIM63,347$8.7M
Russell Investments Group, Ltd.DOUBLED47,892$6.6M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

23 analysts
Buy 96% rate it Buy or better
Strong Buy7Buy15Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Nov 16, 2026🔒 Fresh data, subscribers only
INITIATE
INITIATE
Nov 9, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy
Nov 6, 2026Oppenheimer
MAINTAIN
MAINTAINOutperform
Oct 28, 2026Chardan Capital
MAINTAIN
MAINTAINBuy
Oct 16, 2026William Blair
INITIATE
INITIATEOutperform
Oct 12, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$10.1M
sold · 3 insiders
DateInsiderTypeValue
Nov 11, 2026
Martini Jeffrey S
Chief Scientific Officer
Nov 11, 2026
SELL$243.2K
Nov 11, 2026
Martini Jeffrey S
Chief Scientific Officer
Nov 11, 2026
SELL$188.9K
Nov 11, 2026
Martini Jeffrey S
Chief Scientific Officer
Nov 11, 2026
EXERCISE$61.2K
Nov 11, 2026
Martini Jeffrey S
Chief Scientific Officer
Nov 11, 2026
SELL$101.2K
Nov 11, 2026
Martini Jeffrey S
Chief Scientific Officer
Nov 11, 2026
SELL$34.0K
Nov 11, 2026
Martini Jeffrey S
Chief Scientific Officer
Nov 11, 2026
SELL$270.8K
Nov 11, 2026
Martini Jeffrey S
Chief Scientific Officer
Nov 11, 2026
SELL$201.3K
Nov 10, 2026
Martini Jeffrey S
Chief Scientific Officer
Nov 10, 2026
SELL$33.6K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
2,601,661
shares short
+8.1%
vs prior settlement
11.5
days to cover
≈17.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 11, 2026 Insider
Martini Jeffrey S sold 1,467 shares
Chief Scientific Officer @ $165.78 ($243.2K)
Nov 11, 2026 Insider
Martini Jeffrey S sold 1,133 shares
Chief Scientific Officer @ $166.76 ($188.9K)
Nov 11, 2026 Insider
Martini Jeffrey S acquired via exercise 6,250 shares
Chief Scientific Officer @ $9.79 ($61.2K)
Nov 10, 2026 SEC
{ "summary": "CEO Jeffrey Martini filed a Form 144 notice of intent to sell 50,000 shares of Palvella Therapeutics…
144 · Impact 5/10
Nov 5, 2026 SEC
Palvella reported Q3 2026 net loss of $24.6M ($1.70/share), wider than the $11.3M loss in Q3 2025, driven by increased…
PRESS-RELEASE · Impact 6/10
Nov 5, 2026 Earnings
Palvella Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
FDA Accepts NDA for QTORIN™ Rapamycin and Grants Priority Review for Microcystic Lymphatic Malformat
Oct 28, 2026 Press
Palvella Therapeutics announced FDA acceptance and Priority Review of its NDA for QTORIN rapamycin for microcystic…
Impact 7/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Recent

SecBot reports

26 filings · 10 press releases · 4 bullish · 2 bearish · 1 mixed · 19 neutral
All PVLA filing & press-release reports (36)